Portrait of Almer Van Der Sloot is unavailable

Almer Van Der Sloot

Scientific Facilitator, Scientific Direction

Publications

Multi-Objective Amortized CDRH3 Sequence Sampling Diversifies Promising Antibody Candidates
Quentin Fournier
Robert M. Vernon
Christopher James Langmead
Antibody therapeutics have transformed treatment across diverse therapeutic areas and have become central to modern medicine. While recent m… (see more)achine learning approaches aim to accelerate antibody discovery through structure-based design and target-affinity optimization, successful candidates must also satisfy broad developability constraints, including structural compatibility, low immunogenicity, and favorable biophysical properties, while remaining sufficiently diverse to provide sufficient coverage of design space to mitigate later-stage development failures. We introduce a preference-conditioned multi-objective generative flow network (GFN) fine-tuning pipeline for fixed-framework CDRH3 loop redesign that fine-tunes a biological sequence model against many inexpensive proxies covering backbone compatibility, sequence likelihood, immunogenicity risk, novelty, and developability liabilities. It combines up to fourteen predictive rewards in a single policy trained to sample CDRH3 loops across 623 SAbDab antibody structures, leveraging a reward reduction strategy to preserve Pareto dominance under this learned map. We also introduce a novel autoregressive span-in-filling variant of AMPLIFY-350M that serves both as a scaffold-conditioned CDRH3 generation prior and as a direct conditional likelihood scorer. We evaluated reward scores, diversity, and design quality on loops sampled on 45 held-out antibody complexes to assess structural consistency, confidence, aggregation propensity, stability, and antigen binding. Compared with the inverse-folding methods ProteinMPNN and ESM-IF, our approach produces roughly 10x more distinct acceptable candidates per design at 50% sequence identity, while holding 10% of the 14-objective Pareto front pooled across methods, trading per-sample quality for greater exploration of novel possible structures.
Protein Language Models: Is Scaling Necessary?
Quentin Fournier
Robert M. Vernon
Benjamin Schulz
Christopher James Langmead
Public protein sequence databases contain samples from the fitness landscape explored by nature. Protein language models (pLMs) pre-trained … (see more)on these sequences aim to capture this landscape for tasks like property prediction and protein design. Following the same trend as in natural language processing, pLMs have continuously been scaled up. However, the premise that scale leads to better performance assumes that source databases provide an accurate representation of the underlying fitness landscape, which is likely false. By developing an efficient codebase, designing a modern architecture, and addressing data quality concerns such as sample bias, we introduce AMPLIFY, a best-in-class pLM that is orders of magnitude less expensive to train and deploy than previous models. Furthermore, to support the scientific community and democratize the training of pLMs, we have open-sourced AMPLIFY’s pre-training codebase, data, and model checkpoints.
RGFN: Synthesizable Molecular Generation Using GFlowNets
Andrei Rekesh
Dmytro Shevchuk
Cheng-Hao Liu
Mike Tyers
Robert A. Batey
Generative models hold great promise for small molecule discovery, significantly increasing the size of search space compared to traditional… (see more) in silico screening libraries. However, most existing machine learning methods for small molecule generation suffer from poor synthesizability of candidate compounds, making experimental validation difficult. In this paper we propose Reaction-GFlowNet (RGFN), an extension of the GFlowNet framework that operates directly in the space of chemical reactions, thereby allowing out-of-the-box synthesizability while maintaining comparable quality of generated candidates. We demonstrate that with the proposed set of reactions and building blocks, it is possible to obtain a search space of molecules orders of magnitude larger than existing screening libraries coupled with low cost of synthesis. We also show that the approach scales to very large fragment libraries, further increasing the number of potential molecules. We demonstrate the effectiveness of the proposed approach across a range of oracle models, including pretrained proxy models and GPU-accelerated docking.
Towards DNA-Encoded Library Generation with GFlowNets
Louis Vaillancourt
Doris Alexandra Schuetz
Mathieu Bourgey
Anne Marinier
Generative Active Learning for the Search of Small-Molecule Protein Binders
Cheng-Hao Liu
Éric Jolicoeur
Edward Ruediger
Andrei Nica
Daniel St-Cyr
Doris Alexandra Schuetz
Victor Ion Butoi
Saikrishna Gottipati
Prateek Gupta
Sasikanth Avancha
William Hamilton
Brooks Paige
Sanchit Misra
Bharat Kaul
José Miguel Hernández-Lobato
Marwin Segler
Michael Bronstein
Anne Marinier
Mike Tyers
Despite substantial progress in machine learning for scientific discovery in recent years, truly de novo design of small molecules which exh… (see more)ibit a property of interest remains a significant challenge. We introduce LambdaZero, a generative active learning approach to search for synthesizable molecules. Powered by deep reinforcement learning, LambdaZero learns to search over the vast space of molecules to discover candidates with a desired property. We apply LambdaZero with molecular docking to design novel small molecules that inhibit the enzyme soluble Epoxide Hydrolase 2 (sEH), while enforcing constraints on synthesizability and drug-likeliness. LambdaZero provides an exponential speedup in terms of the number of calls to the expensive molecular docking oracle, and LambdaZero de novo designed molecules reach docking scores that would otherwise require the virtual screening of a hundred billion molecules. Importantly, LambdaZero discovers novel scaffolds of synthesizable, drug-like inhibitors for sEH. In in vitro experimental validation, a series of ligands from a generated quinazoline-based scaffold were synthesized, and the lead inhibitor N-(4,6-di(pyrrolidin-1-yl)quinazolin-2-yl)-N-methylbenzamide (UM0152893) displayed sub-micromolar enzyme inhibition of sEH.
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization
Thomas Gaudelet
Andrew Anighoro
Torsten Gross
Francisco Martínez-Peña
Eileen L. Tang
M.S. Suraj
Cristian Regep
Jeremy B.R. Hayter
Nicholas Valiante
Mike Tyers
Charles E.S. Roberts
Michael M. Bronstein
Luke L. Lairson
Jake P. Taylor-King
RECOVER: sequential model optimization platform for combination drug repurposing identifies novel synergistic compounds in vitro
Thomas Gaudelet
Andrew Anighoro
Torsten Gross
Francisco Martínez-Peña
Eileen L. Tang
Suraj M S
Cristian Regep
Jeremy B. R. Hayter
Nicholas Valiante
Mike Tyers
Charles Roberts
Michael M. Bronstein
Luke L. Lairson
Jake P. Taylor-King